To understand how a diabetes drug touches the vascular system, it helps to start with the hormone it mimics. GLP-1 is an incretin hormone released by enteroendocrine L-cells in the distal ileum and colon after a meal. When glucose or other nutrients arrive in the gut, these cells close ATP-dependent potassium channels, depolarize the membrane, open L-type calcium channels and secrete GLP-1 into the bloodstream. The hormone then amplifies insulin secretion from pancreatic beta cells by two- to three-fold compared with intravenous glucose, a phenomenon known as the incretin effect. It also delays gastric emptying and suppresses glucagon release. In type 2 diabetes, this incretin effect is blunted, partly through impaired GLP-1 function and reduced receptor expression, which is precisely why pharmacological boosting of the pathway has proven so effective.

Native GLP-1, however, is a fleeting molecule. The enzyme dipeptidyl peptidase-4 cleaves it within minutes, leaving a circulating half-life of roughly ninety seconds, so a substantial fraction of the hormone is inactivated before it ever reaches its targets. Therapeutic agonists were engineered to escape this fate. Exenatide, derived from a peptide found in the saliva of the Gila monster, survives for about 2.4 hours and was approved in 2005 for twice-daily injection. Liraglutide carries a fatty-acid side chain that binds reversibly to serum albumin, extending its half-life to 13 to 15 hours after subcutaneous injection. Semaglutide, dulaglutide and albiglutide push persistence further still, with half-lives long enough to permit once-weekly dosing. Tirzepatide adds a second layer of sophistication by engaging the receptor for the other incretin hormone, GIP, as well as GLP-1.

All of these molecules converge on a single target: the GLP-1 receptor, a class B G protein-coupled receptor of 463 amino acids found in the pancreas, gastrointestinal tract, lungs, kidneys, central nervous system and, in mice, monkeys and humans, the heart. When activated, the receptor can couple to the Gs protein to raise cyclic AMP, to Gq/11 to elevate intracellular calcium, and to beta-arrestin to trigger ERK1/2 signaling. Crucially, different ligands bias the receptor toward different downstream cascades, a property known as biased agonism. The review highlights this as one plausible explanation for why structurally distinct agonists do not lower blood pressure to the same degree: they are not simply switching the receptor on, they are steering it toward different intracellular programs.

The vascular story begins in the endothelium. In human umbilical vein endothelial cells exposed to GLP-1, receptor activation recruits the phosphatidylinositol 3-kinase/Akt pathway, which phosphorylates and activates endothelial nitric oxide synthase, raising the bioavailability of nitric oxide, the principal relaxing factor of the vessel wall. A parallel protein kinase A-dependent route to nitric oxide production operates alongside it. Together these converging pathways relax vascular smooth muscle and reduce peripheral resistance. Downstream, activation of AMP-activated protein kinase and suppression of nuclear factor-kappa B signaling cut vascular oxidative stress, adhesion molecule expression and inflammatory cytokine release, linking the acute vasoactive effects of the receptor to the slower, anti-atherosclerotic remodeling of the vessel wall.

The heart and kidneys contribute their own mechanisms. In atrial cardiomyocytes, GLP-1 receptor activation couples to Epac2, triggering the secretion of atrial natriuretic peptide, which raises cyclic GMP and promotes both vasodilation and renal sodium excretion. Direct natriuresis has been documented in healthy, obese and type 2 diabetic individuals, offering a plausible route by which plasma volume, and with it blood pressure, is reduced. Evidence from mouse studies further suggests that exendin-4 can dampen angiotensin II signaling in the kidney, inhibiting the transforming growth factor beta1 and Smad3 pathway that drives fibrosis. Yet here the literature fractures: a clinical study of dulaglutide found no significant changes in plasma renin activity, serum aldosterone or related neurohormonal markers, leaving the role of the renin-angiotensin-aldosterone system unresolved and flagged by the review as a priority for further investigation.

The clinical data, drawn from cardiovascular outcome trials and pooled analyses, paint a picture of modest but persistent effect. Exenatide at 10 micrograms twice daily reduced systolic pressure by a least-squares mean of 2.8 mmHg across 2,171 patients, with the largest difference, 8.2 mmHg versus placebo, seen in people whose baseline systolic pressure exceeded 150 mmHg. Once-weekly exenatide lowered systolic pressure by 1.6 mmHg in the EXSCEL trial of nearly 14,752 patients. Dulaglutide at 1.5 milligrams produced a 2 to 3 mmHg reduction evident within four weeks and sustained through 26 weeks, accompanied by a fall in 24-hour pulse pressure. Semaglutide at 1.0 milligram weekly lowered systolic pressure by 2.6 mmHg in SUSTAIN-6, and oral semaglutide matched that figure at week 83 in PIONEER-6. Liraglutide managed 1.2 mmHg over 36 months in LEADER, while lixisenatide achieved only 0.8 mmHg in ELIXA. Diastolic pressure, by contrast, was largely untouched.

Two patterns emerge from those numbers. First, the effect is drug-specific: agents differ by more than threefold in the magnitude of systolic reduction they deliver, consistent with the biased agonism observed at the receptor. Second, the benefit is conditional. People with normal blood pressure at baseline showed no between-group differences in the trials, suggesting that GLP-1 receptor agonists act as regulators of an elevated system rather than as blanket antihypertensives. The review also draws a careful temporal distinction that has muddied the literature. Acutely, GLP-1 receptor stimulation of sinoatrial node pacemaker cells and brainstem autonomic neurons raises heart rate and can transiently nudge mean arterial pressure upward, particularly after dose escalation. Chronically, sustained therapy produces a net systolic reduction as weight loss, improved glycemic control and the vascular, renal and anti-inflammatory mechanisms accumulate and outweigh the initial pressor response. The two effects operate on different timescales and are not contradictory, but conflating them has fueled apparent inconsistencies across studies.

What the mechanisms cannot yet claim is firm human validation. Aside from the natriuresis and endothelial function data, most of the mechanistic evidence comes from animal models and in vitro systems, and blood pressure was rarely a pre-specified primary endpoint in the major cardiovascular outcome trials from which the clinical numbers are extracted. That makes it difficult to determine whether the observed 1 to 3 mmHg reductions translate into meaningful antihypertensive benefit independent of glycemic control or weight loss, and head-to-head comparisons between agents are lacking. The review calls for trials that place blood pressure at the center of the design, translational studies in human subjects to confirm the proposed nitric oxide, atrial natriuretic peptide and renin-angiotensin pathways, and stratified analyses to identify which patients, most plausibly those with elevated baseline pressure and coexisting type 2 diabetes, stand to gain the most.

Even within those limits, the synthesis carries a striking implication. A drug class developed to restore a gut hormone signal has turned out to engage nearly every major axis of cardiovascular regulation: endothelial nitric oxide signaling, natriuretic peptide release, renal sodium handling, vascular inflammation and atherosclerotic plaque biology. Liraglutide has been shown to suppress angiotensin II-induced inflammatory cascades in vessel walls, preventing the expression of ICAM-1, VCAM-1 and P-selectin on endothelial cells and restoring nitric oxide levels. Exenatide modulates matrix metalloproteinases in human coronary artery cells and shifts macrophages from a pro-inflammatory M1 state toward a reparative M2 phenotype, stabilizing atherosclerotic lesions. Semaglutide and liraglutide reduce plaque development in mice through AMPK activation and lowered proinflammatory cytokines. The blood pressure effect, small as it is, may be the visible surface of a much deeper vascular reprogramming, and understanding it fully could determine how these blockbuster drugs are positioned in the broader campaign against cardiovascular disease.

Subject of Research: Blood pressure regulation by glucagon-like peptide-1 receptor agonists and its cardiovascular mechanisms

Article Title: Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications

Article References: Alharbi, N. H. J. (2026). Glucagon‐Like Peptide‐1 Agonists and Blood Pressure Regulation: Molecular Mechanisms and Cardiovascular Implications. Pharmacology Research & Perspectives, 14(5), Article e70329. https://doi.org/10.1002/prp2.70329

Image Credits: AI Generated

DOI: 10.1002/prp2.70329

Keywords: GLP-1 receptor agonists, blood pressure, hypertension, type 2 diabetes, nitric oxide, endothelial function, natriuresis, atrial natriuretic peptide, cardiovascular outcomes, semaglutide, liraglutide, incretin effect

The PUSH-AHF trial, conducted at the University Medical Center Groningen in the Netherlands, enrolled 310 patients hospitalized with acute heart failure and randomly assigned them in equal numbers to either standard of care or natriuresis-guided diuretic therapy. In the standard-of-care arm, patients received loop diuretics twice daily according to a protocol based on their outpatient diuretic use and baseline kidney function. In the guided arm, clinicians measured spot urinary sodium and urine volume at fixed time points—2, 6, 12, 18, 24, and 36 hours after starting treatment. If urinary sodium fell below 70 millimoles per liter or urine output dropped under 150 milliliters per hour while congestion persisted, the diuretic dose was escalated. The idea is elegant: rather than guessing whether the kidneys are responding, the treatment algorithm reads the kidneys’ answer directly.

The trial’s dual primary endpoints were total sodium excretion in the first 24 hours and, separately, the composite of all-cause mortality or heart failure rehospitalization at 180 days. Of the enrolled patients, 172 were men and 138 were women. In the new analysis, led by Hailun Qin, Lara Zonneveld, and Jozine ter Maaten, the researchers stratified outcomes by sex and adjusted for baseline differences including heart rate, heart failure etiology, prior myocardial infarction, and baseline sodium, potassium, and creatinine levels. What emerged was a striking asymmetry between the sexes that the original trial’s overall neutral result had obscured.

For men, the guided strategy appeared to deliver on its promise. Mean total 24-hour natriuresis was significantly greater in men receiving natriuresis-guided therapy than in those on standard care—443 versus 354 millimoles, a statistically significant difference. Men in the guided arm also achieved the highest cumulative natriuresis and diuresis over 72 hours of any group in the trial. More importantly, the clinical consequences followed: men treated with the guided approach had a 49 percent lower risk of the 180-day composite of heart failure rehospitalization or all-cause death, with an adjusted hazard ratio of 0.51. In-hospital mortality among men on standard care reached 12 percent, while no men on guided therapy died during admission. Men on guided therapy also went home sooner, with a median hospital stay of six days compared with eight days on standard care.

For women, the picture was fundamentally different. Mean 24-hour natriuresis was nearly identical between treatment arms—357 versus 336 millimoles—and the guided strategy produced no reduction in the 180-day composite endpoint; the adjusted hazard ratio of 1.40 pointed, if anything, in the opposite direction, though it was not statistically significant. The formal test of interaction between sex and treatment was significant for the long-term outcome, with a p-value of 0.026, meaning the treatment effect genuinely appeared to differ between men and women rather than reflecting a simple difference in sample size. Women in the guided arm also showed a lower 24-hour natriuretic response—the amount of sodium excreted per milligram of diuretic administered—than women on standard care, at 23 versus 52 millimoles of urinary sodium per milligram of bumetanide equivalent.

The renal safety signals added another layer of complexity. Women receiving natriuresis-guided therapy experienced worsening renal function—defined as a rise in serum creatinine of at least 26.5 micromoles per liter—far more often than women on standard care, at 42 versus 14 percent. Their estimated glomerular filtration rate declined significantly over the admission compared with the near-flat trajectory seen in women on standard care, with the steepest drop occurring in the first 24 hours. Yet, crucially, this renal worsening was not associated with worse clinical outcomes at 180 days in either sex, echoing findings from other trials such as CLOROTIC. The authors argue that the safety data overall are reassuring, supporting natriuresis-guided therapy as well tolerated regardless of sex, while acknowledging that the renal changes in women warrant confirmation in larger studies.

Why might men and women respond so differently to the same physiological logic? Several hypotheses deserve consideration. One candidate is heart failure phenotype itself: men more commonly present with heart failure with reduced ejection fraction, while women more often have the preserved-ejection-fraction form, which involves different underlying physiology of stiffness and congestion. In the ROSE-AHF trial, decongestion strategies improved urine output in patients with reduced ejection fraction but not in those with preserved ejection fraction. PUSH-AHF could not test this directly, because baseline ejection fraction was missing in about a quarter of patients, making adjustment for phenotype impossible. Pharmacokinetics offer another clue: for the loop diuretic torsemide, women show a 1.5-fold higher drug exposure and one-third lower oral clearance than men, suggesting sex-dependent handling of these drugs that could alter both efficacy and renal tolerance.

The authors are careful to frame these results as exploratory and hypothesis-generating rather than practice-changing. The sex-stratified analysis was conducted post hoc, the trial was single-center and open-label, dietary sodium intake—an important determinant of urinary sodium—was not controlled, and the number of events, particularly among women, was small. It remains possible that the apparent benefit in men partly reflects unusually poor outcomes in the standard-care group, or that chance, residual confounding, and limited statistical power explain the divergence. Notably, the overall risk of death or rehospitalization at 180 days was markedly lower in women than in men regardless of treatment, which may have left less room for a guided strategy to demonstrate benefit.

What the analysis does establish is that the absence of benefit in women should not be read as a reason to withhold natriuresis-guided therapy from them. The authors explicitly state that the observed sex-specific patterns do not support denying the strategy to women; instead, they highlight the need to investigate whether the optimal marker, threshold, dosing approach, or renal tolerance of decongestion differs by sex and heart failure phenotype. Prior evidence already shows that women derive different magnitudes of benefit from other heart failure drugs—appearing to gain more from sacubitril/valsartan and spironolactone, and reaching lowest risk at lower target doses of ACE inhibitors and beta-blockers than men—so a sex-dependent response to decongestion would fit a broader pattern rather than stand alone.

The broader significance of the study lies in what it says about precision medicine’s blind spots. Urinary sodium is increasingly embraced as a real-time biomarker of diuretic effectiveness, and the European Society of Cardiology guidelines already recommend evaluating diuretic response during hospitalization. A meta-analysis of 19 studies has linked higher urinary sodium to greater weight loss, shorter hospital stays, and lower mortality. If the PUSH-AHF findings hold up in adequately powered, multi-center prospective trials, the next generation of decongestion protocols may need sex-specific targets and escalation rules—and clinicians may finally have a data-driven answer to the question of why two patients given the same diuretic can respond so differently. Until then, the trial stands as a vivid reminder that even the oldest tools in cardiology still hold secrets worth measuring, one urine sample at a time.

Subject of Research: Sex-specific effects of natriuresis-guided diuretic therapy in acute heart failure

Article Title: Effects of natriuresis-guided diuretic therapy in men and women with acute heart failure: insights from PUSH-AHF

Article References: Qin, H., Zonneveld, L. E. E. C., Voors, A. A., Beldhuis, I. E., Ravera, A., van Veldhuisen, D. J., Coster, J. E., Nieuwland, W., Krikken, J. A., van der Meer, P., Damman, K., & ter Maaten, J. M. (2026). Effects of natriuresis-guided diuretic therapy in men and women with acute heart failure: insights from PUSH-AHF. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03030-1

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03030-1

Keywords: acute heart failure, natriuresis, diuretic therapy, loop diuretics, urinary sodium, sex differences, PUSH-AHF trial, decongestion, worsening renal function, rehospitalization, precision medicine, cardiology